The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines ...faster over the three-year estimated life of an ITN; therefore, the added impact of
pyrethroid-PBO ITNs over that of pyrethroid-only LLINs may decline over time. The evidence comes from two sites in
eastern Africa with pyrethroid resistance and not from other geographies where transmission levels and vector characteristics
may vary. PBO acts by inhibiting certain metabolic enzymes, primarily oxidases, and so are likely to provide greater protection
than pyrethroid-only LLINs where mosquitoes display mono-oxygenase-based insecticide resistance mechanisms.
more
MEDBOX Issue Brief No.17, 21 November 2021
Women's cancers have a significant impact on women's health worldwide. According to the World Health Organisation, nearly three million women are diagnosed with breast or cervical cancer every year. In this Issue Brief you will find more information.
Towards attaining the highest standard Health.
Mental health problems represent the greatest global burden of disease among children and adolescents. There is, however, lack of policy development and implementation for child and adolescent mental health (CAMH), particularly in low- and middle-income countries (LMICs) where children and adolescen...ts represent up to 50% of populations. South Africa, an upper-middle income country is often regarded as advanced in health and social policy-making and implementation in comparison to other LMICs. It is, however, not clear whether this is the case for CAMH.
more
This report highlights the work of the World Health Organization (WHO) in Zimbabwe towards contributing to the triple billion targets in the context of the Sustainable Development Goals (SDGs
Expanding access to quality health services through task sharing
International Journal of Drug Policy 24 (2013) e91-98